Impact of Lymphadenectomy on Survival of Patients with Serous Advanced Ovarian Cancer After Neoadjuvant Chemotherapy: A French National Multicenter Study (FRANCOGYN).

Fiche publication

Date publication

juillet 2020

Journal

Journal of clinical medicine

Auteurs

Membres identifiés du Cancéropôle Est :
Pr BALDAUF Jean-Jacques , Pr COUTANT Charles , Pr VELTEN Michel , Dr DEMARCHI Martin , Dr GANTZER Justine , Pr AKLADIOS Chérif

Tous les auteurs :
Bund V, Lecointre L, Velten M, Ouldamer L, Bendifallah S, Koskas M, Bolze PA, Collinet P, Canlorbe G, Touboul C, Huchon C, Coutant C, Faller E, Boisramé T, Gantzer J, Demarchi M, Baldauf JJ, Ballester M, Lavoué V, Akladios C

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32751303

Résumé

The population of interest to this study comprised individuals with advanced-stage ovarian carcinoma who were exposed to neoadjuvant chemotherapy (NAC) followed by interval debulking surgery (IDS). Those who had not received systematic lymphadenectomy (SL; Group 1) were compared to those who had received SL (Group 2). Outcome measures included progression-free survival (PFS), overall survival (OS), and surgical complications.